Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Abbott reports novel HDAC inhibitors at the ACS meeting

Aug. 20, 2002

Ras-MAPK signaling cascade inhibitors prepared and tested at Wyeth

Aug. 20, 2002

Potent, selective and orally bioavailable FTase inhibitor presented by Abbott

Aug. 20, 2002

Iressa NSCLC trial results show no improvement in combined treatment with standard chemotherapy

Aug. 20, 2002

Salicylate protects against the ototoxic and nephrotoxic side effects of cisplatin in rats

Aug. 20, 2002

Phase I solid tumor trial initiated for KSP inhibitor

Aug. 20, 2002

ARC enters research agreement with McGill University for antisense oligonucleotide therapeutics

Aug. 20, 2002

Interferon inducers described by Sumitomo and Japan Energy at ACS meeting

Aug. 19, 2002

Enrollment initiated in phase III atamestane trial

Aug. 19, 2002

Viragen and U. of Miami collaborate on immune enhancing drug for cancer

Aug. 19, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.